» Articles » PMID: 28571100

Diagnosis and New Treatment Avenues in Spinal Muscular Atrophy

Overview
Journal Neuropediatrics
Specialty Pediatrics
Date 2017 Jun 2
PMID 28571100
Citations 11
Authors
Affiliations
Soon will be listed here.
Citing Articles

Effects of nusinersen on motor function in children with spinal muscular atrophy: a retrospective study.

Chen Y, Yang D, Huang X, Feng J, Zhao Q, Huang H Front Neurol. 2024; 15:1391613.

PMID: 39076847 PMC: 11284043. DOI: 10.3389/fneur.2024.1391613.


Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China.

Li D, Yang J, Wang X, Yang L, Luo R, Huang S Brain Behav. 2024; 14(7):e3630.

PMID: 39034388 PMC: 11260551. DOI: 10.1002/brb3.3630.


Quality considerations and major pitfalls for high throughput DNA-based newborn screening for severe combined immunodeficiency and spinal muscular atrophy.

Bzdok J, Czibere L, Burggraf S, Landt O, Maier E, Roschinger W PLoS One. 2024; 19(6):e0306329.

PMID: 38941330 PMC: 11213327. DOI: 10.1371/journal.pone.0306329.


5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2.

Vill K, Tacke M, Konig A, Baumann M, Baumgartner M, Steinbach M J Neurol. 2024; 271(5):2787-2797.

PMID: 38409538 PMC: 11055798. DOI: 10.1007/s00415-024-12188-5.


Natural history of spinal muscular atrophy in children: an analysis of 117 cases.

Yang Y, Yuan P, Li M, Jiang L, Hong S Zhongguo Dang Dai Er Ke Za Zhi. 2021; 23(10):1038-1043.

PMID: 34719420 PMC: 8549636. DOI: 10.7499/j.issn.1008-8830.2106025.